Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.

about

From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.hsa‑miR‑24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‑Myc/epithelial‑mesenchymal transition axis

P2860

Q50351390-27675BCE-F3AB-4FE1-AF35-963A2D71E244 Q58758617-9451AF1E-7AE3-4344-B1C7-20F4AE996BD1

P2860

Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.

Item

http://www.wikidata.org/entity/Q48588785

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Synthetic lethality of PARP in ...... triple negative breast cancer.

@en

Synthetic lethality of PARP in ...... triple negative breast cancer.

@nl

type

Item

label

Synthetic lethality of PARP in ...... triple negative breast cancer.

@en

Synthetic lethality of PARP in ...... triple negative breast cancer.

@nl

prefLabel

Synthetic lethality of PARP in ...... triple negative breast cancer.

@en

Synthetic lethality of PARP in ...... triple negative breast cancer.

@nl

P1476

Synthetic lethality of PARP in ...... triple negative breast cancer.

@en

P2093

Cansu Karakas

http://www.w3.org/2001/XMLSchema#string

Jason P W Carey

http://www.w3.org/2001/XMLSchema#string

Jennifer K Litton

http://www.w3.org/2001/XMLSchema#string

Jing Wang

http://www.w3.org/2001/XMLSchema#string

Keith Mikule

http://www.w3.org/2001/XMLSchema#string

Kelly K Hunt

http://www.w3.org/2001/XMLSchema#string

Khandan Keyomarsi

http://www.w3.org/2001/XMLSchema#string

Tuyen Bui

http://www.w3.org/2001/XMLSchema#string

Xian Chen

http://www.w3.org/2001/XMLSchema#string

Yang Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

MYC, Metabolism, and Cancer

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

A new mathematical model for relative quantification in real-time RT-PCR

Repeated observation of breast tumor subtypes in independent gene expression data sets

RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Rad51 supports triple negative breast cancer metastasis.

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

P304

742-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-17-1494

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Smruthi Vijayaraghavan

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29180466

http://www.w3.org/2001/XMLSchema#string

P932

5811386

http://www.w3.org/2001/XMLSchema#string

Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.

about

P2860

P2860

Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932